Neuroblastoma patients with GD2+/CD81+/CD56+/CD45– cells in BM by FMC had significantly worse event-free survival and increased cumulative incidence of relapse/progression (94) (Table 4). This evidence concerns the gene PTPRC and neuroblastoma.